Valeant Pharmaceuticals International Inc. is looking to issue $1.25 billion in fresh debt to repurchase some of its existing notes.
The Canadian specialty drugmaker will price the offering at a later date. The company is looking to repurchase its existing 6.375% senior notes due 2020, 5.375% senior notes due 2020, and up to $100.0 million principal amount of its 6.750% senior notes due 2021.
The tender offer to repurchase the notes expires 11:59 p.m. ET on April 9.
